GTS Biotech
GTS Biotech is a forward-thinking biotech company dedicated to revolutionizing cancer and immunology treatment through the discovery and development of compounds derived from natural sources. They focus on harnessing the potential of natural compounds to unlock new frontiers in oncology, immunology, and other research areas, aiming to offer hope to patients fighting against cancer. Their mission emphasizes nature's wisdom, cutting-edge research, personalized therapies, safety and efficacy, and sustainability.
Industries
Nr. of Employees
small (1-50)
GTS Biotech
Spring Hill, Tennessee, United States, North America
Patents
Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
US-10894030-B2
View Details
Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
US-10894030-B2
View DetailsProducts
CTB-1
A natural-compound therapeutic candidate derived primarily from cinnamon bark that has been reported to exhibit selective anti-cancer activity; has progressed to regulatory review and has received orphan drug and rare pediatric disease designations.
CTD-1
A natural-compound candidate identified in cinnamon bark reported to have anti-cancer and immunomodulatory activity; positioned as a potential therapeutic for oncology and autoimmune/inflammatory conditions.
Cinnamtannin B-1
Cinnamtannin B-1 is a natural compound that inhibits the progression of osteosarcoma by regulating the miR-1281/PPIF axis. It has received orphan drug designation from the FDA as a treatment for osteosarcoma and rare pediatric disease designation.
CTB-1
A natural-compound therapeutic candidate derived primarily from cinnamon bark that has been reported to exhibit selective anti-cancer activity; has progressed to regulatory review and has received orphan drug and rare pediatric disease designations.
CTD-1
A natural-compound candidate identified in cinnamon bark reported to have anti-cancer and immunomodulatory activity; positioned as a potential therapeutic for oncology and autoimmune/inflammatory conditions.
Cinnamtannin B-1
Cinnamtannin B-1 is a natural compound that inhibits the progression of osteosarcoma by regulating the miR-1281/PPIF axis. It has received orphan drug designation from the FDA as a treatment for osteosarcoma and rare pediatric disease designation.
Services
Partnerships to co-develop natural-compound therapeutic candidates and advance programs through preclinical and clinical stages.
Advisory support from in-house leadership and external advisors with experience in clinical development and industry translation.
Partnerships to co-develop natural-compound therapeutic candidates and advance programs through preclinical and clinical stages.
Advisory support from in-house leadership and external advisors with experience in clinical development and industry translation.
Expertise Areas
- Natural product drug discovery
- Oncology drug development
- Immunotherapy development
- Preclinical pharmacology and mechanism studies
Key Technologies
- Natural product extraction and isolation
- Preclinical in vivo oncology models
- Mechanism-of-action pharmacology assays
- Clinical trial methodologies
News & Updates
An article about progress in cancer immunotherapy with CTD-1.
Announcement of FDA designation for CTB-1.
FDA approval for CTB-1 as a treatment for osteosarcoma.
Research on Cinnamtannin B-1's effects on osteosarcoma.
Study on the autoimmune activity of CTD-1.
Announcement of FDA review for CTB-1.
An article about progress in cancer immunotherapy with CTD-1.
Announcement of FDA designation for CTB-1.
FDA approval for CTB-1 as a treatment for osteosarcoma.
Research on Cinnamtannin B-1's effects on osteosarcoma.
Study on the autoimmune activity of CTD-1.
Announcement of FDA review for CTB-1.